Phosphodiesterase Inhibitors
"Phosphodiesterase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases.
| Descriptor ID |
D010726
|
| MeSH Number(s) |
D27.505.519.389.735
|
| Concept/Terms |
Phosphodiesterase Inhibitors- Phosphodiesterase Inhibitors
- Phosphodiesterase Antagonists
- Phosphoric Diester Hydrolase Inhibitors
- Antiphosphodiesterases
|
Below are MeSH descriptors whose meaning is more general than "Phosphodiesterase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Phosphodiesterase Inhibitors".
This graph shows the total number of publications written about "Phosphodiesterase Inhibitors" by people in this website by year, and whether "Phosphodiesterase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Phosphodiesterase Inhibitors" by people in Profiles.
-
Charnigo RJ, Beidler D, Rybin D, Pittman DD, Tan B, Howard J, Michelson AD, Frelinger AL, Clarke N. PF-04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placebo-Controlled Study. Clin Transl Sci. 2019 03; 12(2):180-188.
-
M?nzel T, Gori T, Keaney JF, Maack C, Daiber A. Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications. Eur Heart J. 2015 Oct 07; 36(38):2555-64.
-
Tan X, Sanderson MJ. Bitter tasting compounds dilate airways by inhibiting airway smooth muscle calcium oscillations and calcium sensitivity. Br J Pharmacol. 2014 Feb; 171(3):646-62.
-
E X, Pickering MT, Debatis M, Castillo J, Lagadinos A, Wang S, Lu S, Kowalik TF. An E2F1-mediated DNA damage response contributes to the replication of human cytomegalovirus. PLoS Pathog. 2011 May; 7(5):e1001342.
-
Michelson AD. Advances in antiplatelet therapy. Hematology Am Soc Hematol Educ Program. 2011; 2011:62-9.
-
Silver B, McCarthy S, Lu M, Mitsias P, Russman AN, Katramados A, Morris DC, Lewandowski CA, Chopp M. Sildenafil treatment of subacute ischemic stroke: a safety study at 25-mg daily for 2 weeks. J Stroke Cerebrovasc Dis. 2009 Sep-Oct; 18(5):381-3.
-
Ellsworth P, Kirshenbaum EM. Current concepts in the evaluation and management of erectile dysfunction. Urol Nurs. 2008 Oct; 28(5):357-69.
-
Zhang L, Zhang Z, Zhang RL, Cui Y, LaPointe MC, Silver B, Chopp M. Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke. Brain Res. 2006 Nov 06; 1118(1):192-8.
-
Silver B, Grover KM, Arcila X, Mitsias PD, Bowyer SM, Chopp M. Recovery in a patient with locked-in syndrome. Can J Neurol Sci. 2006 May; 33(2):246-9.
-
Shabsigh R, Burnett AL, Eardley I, Sharlip ID, Ellsworth PI, Garcia CS, Natanegara F, Ahuja S. Time from dosing to sexual intercourse attempts in men taking tadalafil in clinical trials. BJU Int. 2005 Oct; 96(6):857-63.